Filtered library · Theme
Rare disease & gene therapy theme · 2 dossiers
Dossiers in the Rare disease & gene therapy theme — 2 stocks moving on the same story.
DormantLast worked 7 August 2026, 65 days ago; the research counts a theme as current for 14 days.
All 2 are dated research with a published kill line — the level named in advance that would prove the call wrong.
All dossiers CYRX CryoPort, Inc. Medium Cryoport's cell and gene therapy cold-chain business turned to positive adjusted EBITDA in Q2, and its shares have cooled to $16.90 from an $18.14 high. The ~4 November 2026 third-quarter report shows whether that profit repeats and… OMER Omeros Corporation Medium Omeros Corporation's case rests on YARTEMLEA net product sales growing past the second quarter's $28.5 million; the third-quarter 2026 report, expected around 12 November 2026, settles it.